Contact
searchSearch
HMP Global

Rheumatology

Featured Article

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
Payer Coverage Decisions Shape Access to Myasthenia Gravis Therapies
03/12/2026
Grace Taylor, MS, MA
Payer coverage design, beyond drug cost alone, is shaping patient access to emerging myasthenia gravis therapies and driving the need for more flexible, individualized treatment models.
Payer coverage design, beyond drug cost alone, is shaping patient access to emerging myasthenia gravis therapies and driving the need for more flexible, individualized treatment models.
Payer coverage design, beyond...
03/12/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care

Newsfeed

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care
Behind the Bill
Medicare Cost Cap Act Would Establish Out-of-Pocket Maximum in Traditional Medicare
06/26/2026
Grace Taylor, MS, MA
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would...
06/26/2026
First Report Managed Care
News
Omalizumab Associated With Reduced HCRU and Disease-Related Costs for Food Allergies and Asthma
06/25/2026
Rebecca Amrick
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in...
06/25/2026
First Report Managed Care
News
Social Determinants of Health Negatively Impact Mortality Among Patients With ESKD
06/24/2026
Rebecca Amrick
A systematic review of end-stage kidney disease (ESKD) studies identified multiple health disparities across various domains, highlighting the connection between access barriers and ESKD mortality.
A systematic review of end-stage kidney disease (ESKD) studies identified multiple health disparities across various domains, highlighting the connection between access barriers and ESKD mortality.
A systematic review of end-stage...
06/24/2026
First Report Managed Care
News
Outpatient Cilta-Cel Administration May Reduce Health Care Utilization in RRMM
06/23/2026
Rebecca Amrick
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care...
06/23/2026
First Report Managed Care
News
Impact of Comorbidities on Treatment Patterns and Survival Outcomes in Advanced NSCLC Following ICI Introduction
06/22/2026
Rebecca Amrick
A real-world study found that using immune checkpoint inhibitors (ICIs) to treat non–small cell lung cancer (NSCLC) expanded the use of systemic anticancer treatment (SACT) and significantly increased survival outcomes, even among patients...
A real-world study found that using immune checkpoint inhibitors (ICIs) to treat non–small cell lung cancer (NSCLC) expanded the use of systemic anticancer treatment (SACT) and significantly increased survival outcomes, even among patients...
A real-world study found that...
06/22/2026
First Report Managed Care
News
A Race-Free eGFR Formula Could Improve Care for Patients With Kidney Disease
06/22/2026
Rebecca Amrick
A growing transition to a race-free estimated glomerular filtration rate (eGFR) formula marks a significant step toward more accurate, equitable care for patients with kidney disease, particularly for medication prescription.
A growing transition to a race-free estimated glomerular filtration rate (eGFR) formula marks a significant step toward more accurate, equitable care for patients with kidney disease, particularly for medication prescription.
A growing transition to a...
06/22/2026
First Report Managed Care
Behind the Bill
DOJ and Ohio Attorney General Challenge OhioHealth Managed Care Contracting Practices
06/19/2026
Grace Taylor, MS, MA
Federal and Ohio regulators allege OhioHealth used anticompetitive contracting provisions that limited insurer network design and increased health care costs.
Federal and Ohio regulators allege OhioHealth used anticompetitive contracting provisions that limited insurer network design and increased health care costs.
Federal and Ohio regulators...
06/19/2026
First Report Managed Care
News
Talquetamab Shows Lower Cost Per Response in Relapsed or Refractory Multiple Myeloma
06/16/2026
Lisa Kuhns, PhD, MD
Talquetamab delivered more than double the response rate of usual care while lowering the cost per responder, highlighting its potential economic and clinical value for heavily pretreated patients with relapsed or refractory multiple myeloma.
Talquetamab delivered more than double the response rate of usual care while lowering the cost per responder, highlighting its potential economic and clinical value for heavily pretreated patients with relapsed or refractory multiple myeloma.
Talquetamab delivered more than...
06/16/2026
First Report Managed Care
News
Integrated CKD Care Models Could Improve Early Detection and Outcomes
06/15/2026
Hannah Musick
Population health management strategies that combine early chronic kidney disease (CKD) detection, risk stratification, and integrated primary-nephrology care may help reduce disease progression, cardiovascular complications, and health care...
Population health management strategies that combine early chronic kidney disease (CKD) detection, risk stratification, and integrated primary-nephrology care may help reduce disease progression, cardiovascular complications, and health care...
Population health management...
06/15/2026
First Report Managed Care
Behind the Bill
CMS Tightens Oversight of Medicaid Demonstration Programs and State-Directed Payments
06/12/2026
Grace Taylor, MS, MA
As the Centers for Medicare & Medicaid Services (CMS) intensifies its review of Medicaid demonstration waivers and state-directed payments, managed care stakeholders are assessing what heightened federal scrutiny could mean for program...
As the Centers for Medicare & Medicaid Services (CMS) intensifies its review of Medicaid demonstration waivers and state-directed payments, managed care stakeholders are assessing what heightened federal scrutiny could mean for program...
As the Centers for Medicare &...
06/12/2026
First Report Managed Care

Insights

Interview
Lower Costs, Improved Outcomes for Patients Achieving Early RA Remission
07/23/2019
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD,...
07/23/2019
First Report Managed Care
Interview
Impact of Artificial Intelligence on Patient Outcomes, Cost of Care in RA
06/20/2019
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar...
06/20/2019
First Report Managed Care
Interview
High Out-of-Pocket Costs Increase Medication Nonadherence Among Patients With RA
06/06/2019
Julie Gould
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at...
06/06/2019
First Report Managed Care
Interview
Techniques Used to Lessen Opioid Use, Address Rheumatologic Pain
05/09/2019
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending...
05/09/2019
First Report Managed Care
Interview
Why Higher Levels of Physical Activity Are Important in Preventing Chronic Diseases
04/11/2019
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD,...
04/11/2019
First Report Managed Care
Interview
Assessing the Safety of a Treatment With A Label Warning for Patients With RA, COPD
04/08/2019
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of...
04/08/2019
First Report Managed Care
Interview
Exploring the Cost Benefits of Cloud-Enabled Testing for RA Diagnosis
03/14/2019
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research...
03/14/2019
First Report Managed Care
Interview
Improving Access to Care, Outcomes Through Telemedicine for Patients With RA
03/06/2019
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate...
03/06/2019
First Report Managed Care
MANAGED CARE Q&A
From Innovation to Access: Overcoming Reimbursement Challenges for Cell and Gene Therapies
06/25/2026
Joe DePinto
This interview explores the structural, operational, and reimbursement challenges limiting access to cell and gene therapies, highlighting the importance of stakeholder collaboration, innovative payment models, real-world evidence, and...
This interview explores the structural, operational, and reimbursement challenges limiting access to cell and gene therapies, highlighting the importance of stakeholder collaboration, innovative payment models, real-world evidence, and...
This interview explores the...
06/25/2026
First Report Managed Care
Debra Patt
Interview
How Electronic Patient-Reported Outcomes Are Transforming Symptom Management and Value-Based Cancer Care
06/19/2026
Debra A. Patt, MD, PhD, MBA
In this interview, Deborah Patt, MD, PhD, MBA, discusses data presented at the 2026 American Society of Clinical Oncology Annual Meeting showing how electronic patient-reported outcomes and remote therapeutic monitoring can improve symptom...
In this interview, Deborah Patt, MD, PhD, MBA, discusses data presented at the 2026 American Society of Clinical Oncology Annual Meeting showing how electronic patient-reported outcomes and remote therapeutic monitoring can improve symptom...
In this interview, Deborah Patt,...
06/19/2026
First Report Managed Care
Jill Hellmann
Interview
Rethinking Cancer Attribution in Value-Based Oncology Care
06/03/2026
Jill Hellmann, MSN, RN
In this interview, a guest expert discusses research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on how the growing use of oral oncolytics and the increasing prevalence of concurrent cancers may expose...
In this interview, a guest expert discusses research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on how the growing use of oral oncolytics and the increasing prevalence of concurrent cancers may expose...
In this interview, a guest...
06/03/2026
First Report Managed Care
Nephrology, kidney disease
Managed Care Insights
The Evolving Nephrology Landscape: Treatment, Innovation, and Policy: Part 3
05/29/2026
Suzanne Watnick, MD
Suzanne Watnick, MD, explains why earlier chronic kidney disease detection, broader access to proven therapies, and reimbursement policies that support innovation are critical to improving kidney care outcomes and reducing progression to...
Suzanne Watnick, MD, explains why earlier chronic kidney disease detection, broader access to proven therapies, and reimbursement policies that support innovation are critical to improving kidney care outcomes and reducing progression to...
Suzanne Watnick, MD, explains...
05/29/2026
First Report Managed Care
Nephrology, kidney disease
Managed Care Insights
The Evolving Nephrology Landscape: Treatment, Innovation, and Policy: Part 2
05/29/2026
Suzanne Watnick, MD
Dr Suzanne Watnick examines how greater investment, equitable policies, and stakeholder collaboration will be essential to ensuring that emerging kidney therapies improve outcomes without widening existing disparities in care.
Dr Suzanne Watnick examines how greater investment, equitable policies, and stakeholder collaboration will be essential to ensuring that emerging kidney therapies improve outcomes without widening existing disparities in care.
Dr Suzanne Watnick examines how...
05/29/2026
First Report Managed Care
Nephrology, kidney disease
Managed Care Insights
The Evolving Nephrology Landscape: Treatment, Innovation, and Policy
05/29/2026
Suzanne Watnick, MD
Dr Suzanne Watnick explains how value-based kidney care can improve outcomes by shifting focus upstream to earlier chronic kidney disease intervention, prevention, and long-term cost savings.
Dr Suzanne Watnick explains how value-based kidney care can improve outcomes by shifting focus upstream to earlier chronic kidney disease intervention, prevention, and long-term cost savings.
Dr Suzanne Watnick explains how...
05/29/2026
First Report Managed Care
CO
Interview
Behavioral Science as Infrastructure: Rethinking Adherence, Engagement, and Managed Care Decision-Making
04/23/2026
Chandra Y. Osborn, PhD, MPH
A member of our First Report Managed Care Editorial Advisory Board explains why managed care decisions hinge on confidence over speed—and how embedding behavioral science across the care continuum can close adherence gaps, activate patients,...
A member of our First Report Managed Care Editorial Advisory Board explains why managed care decisions hinge on confidence over speed—and how embedding behavioral science across the care continuum can close adherence gaps, activate patients,...
A member of our First Report...
04/23/2026
First Report Managed Care
Advanced Squamous Cell Carcinoma of the Anal Canal
Videos
Evaluating Retifanlimab for Advanced Squamous Cell Carcinoma of the Anal Canal in the Frontline Setting
03/31/2026
Lingbin Meng, MD, PhD
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how adding retifanlimab to chemotherapy may reshape frontline treatment for advanced squamous cell carcinoma of the anal canal.
Lingbin Meng, MD, discusses how...
03/31/2026
Journal of Clinical Pathways
Al B. Benson, III, MD, FACP, FASCO
Videos
First-Line Immunotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC): Evidence Review
03/31/2026
Al B. Benson, III, MD, FACP, FASCO
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the epidemiology and unmet clinical need in advanced squamous cell carcinoma of the anal canal (SCAC) and examines the evolving role of immunotherapy in the first-line setting. He also contextualizes recent regulatory and...
Dr Benson reviews the...
03/31/2026
First Report Managed Care
Videos
Can Agentic AI Deliver? Rethinking Innovation, ROI, and Risk in Managed Care
03/30/2026
Andy De, CMO
A guest expert explains why generative AI has largely stalled in health care and argues that agentic AI—focused on automating workflows and driving action—offers a more practical path to measurable ROI, improved clinician productivity, and...
A guest expert explains why generative AI has largely stalled in health care and argues that agentic AI—focused on automating workflows and driving action—offers a more practical path to measurable ROI, improved clinician productivity, and...
A guest expert explains why...
03/30/2026
First Report Managed Care
First Report Managed Care

Current Issue

June 2026
Volume 23
Issue 2
Current Issue
Issue Archive

Recent Stories

News
Machine Learning Models Identify Patients With Rheumatoid Arthritis At Risk for Treatment Nonadherence
03/20/2026
Lisa Kuhns, PhD, MD
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help clinicians pinpoint which older patients with rheumatoid arthritis are most likely to fall off therapy—before it happens.
Machine learning models may help...
03/20/2026
First Report Managed Care
News
Payer Coverage Decisions Shape Access to Myasthenia Gravis Therapies
03/12/2026
Grace Taylor, MS, MA
Payer coverage design, beyond drug cost alone, is shaping patient access to emerging myasthenia gravis therapies and driving the need for more flexible, individualized treatment models.
Payer coverage design, beyond drug cost alone, is shaping patient access to emerging myasthenia gravis therapies and driving the need for more flexible, individualized treatment models.
Payer coverage design, beyond...
03/12/2026
First Report Managed Care
News
No Increased Multiple Myeloma Risk Found With Biologic or Targeted DMARD Use in Veterans With Rheumatoid Arthritis
10/07/2025
Grace Taylor, MS, MA
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health Administration (VHA) study found no significant difference in multiple myeloma incidence between patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs...
A large Veterans Health...
10/07/2025
First Report Managed Care
News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use